113 related articles for article (PubMed ID: 28843749)
1. Evaluation of expression of genes CADM1, TWIST1 and CDH1 by immunohistochemestry in melanocytic lesions.
Munhoz de Paula Alves Coelho K; Stall J; Fronza Júnior H; Blasius R; de França PHC
Pathol Res Pract; 2017 Sep; 213(9):1067-1071. PubMed ID: 28843749
[TBL] [Abstract][Full Text] [Related]
2. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
3. Impact of E-cadherin expression pattern in melanocytic nevi and cutaneous malignant melanoma.
Seleit IA; Samaka RM; Basha MA; Bakry OA
Anal Quant Cytopathol Histpathol; 2012 Aug; 34(4):204-13. PubMed ID: 23016467
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
5. α-Methylacyl-coenzyme A racemase (AMACR, p504s) is a marker to distinguish malignant melanomas from dysplastic nevi and melanocytic nevi.
Abbas M; Ploch EM; Wehling J; Schipper E; Janciauskiene S; Kreipe HH; Jonigk D
Tumour Biol; 2014 Dec; 35(12):12015-20. PubMed ID: 25149154
[TBL] [Abstract][Full Text] [Related]
6. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.
Buehler D; Hardin H; Shan W; Montemayor-Garcia C; Rush PS; Asioli S; Chen H; Lloyd RV
Mod Pathol; 2013 Jan; 26(1):54-61. PubMed ID: 22899291
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Kiszner G; Wichmann B; Nemeth IB; Varga E; Meggyeshazi N; Teleki I; Balla P; Maros ME; Penksza K; Krenacs T
Virchows Arch; 2014 May; 464(5):603-12. PubMed ID: 24682564
[TBL] [Abstract][Full Text] [Related]
8. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.
Phadke PA; Rakheja D; Le LP; Selim MA; Kapur P; Davis A; Mihm MC; Hoang MP
Am J Surg Pathol; 2011 May; 35(5):656-69. PubMed ID: 21436676
[TBL] [Abstract][Full Text] [Related]
9. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
10. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
11. CADM1 is a TWIST1-regulated suppressor of invasion and survival.
Hartsough EJ; Weiss MB; Heilman SA; Purwin TJ; Kugel CH; Rosenbaum SR; Erkes DA; Tiago M; HooKim K; Chervoneva I; Aplin AE
Cell Death Dis; 2019 Mar; 10(4):281. PubMed ID: 30911007
[TBL] [Abstract][Full Text] [Related]
12. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
13. Adipophilin expression in cutaneous malignant melanoma.
Fujimoto M; Matsuzaki I; Yamamoto Y; Yoshizawa A; Warigaya K; Iwahashi Y; Kojima F; Furukawa F; Murata SI
J Cutan Pathol; 2017 Mar; 44(3):228-236. PubMed ID: 27886404
[TBL] [Abstract][Full Text] [Related]
14. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel noninvasive adhesive patch test for the evaluation of pigmented lesions of the skin.
Gerami P; Alsobrook JP; Palmer TJ; Robin HS
J Am Acad Dermatol; 2014 Aug; 71(2):237-44. PubMed ID: 24906614
[TBL] [Abstract][Full Text] [Related]
16. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.
Koh SS; Opel ML; Wei JP; Yau K; Shah R; Gorre ME; Whitman E; Shitabata PK; Tao Y; Cochran AJ; Abrishami P; Binder SW
Mod Pathol; 2009 Apr; 22(4):538-46. PubMed ID: 19270649
[TBL] [Abstract][Full Text] [Related]
17. E-Cadherin Expression in Canine Melanocytic Tumors: Histological, Immunohistochemical, and Survival Analysis.
Silvestri S; Porcellato I; Mechelli L; Menchetti L; Iussich S; De Maria R; Sforna M; Bongiovanni L; Brachelente C
Vet Pathol; 2020 Sep; 57(5):608-619. PubMed ID: 32578507
[TBL] [Abstract][Full Text] [Related]
18. [Thermographic examination of cutaneous melanocytic nevi].
Mikulska D
Ann Acad Med Stetin; 2009; 55(1):31-8; discussion 38. PubMed ID: 20349589
[TBL] [Abstract][Full Text] [Related]
19. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
20. Rate of Immunohistochemistry Utilization in the Diagnosis of Cutaneous Melanocytic Lesions.
Chen TC; Hitchcock MG
Am J Dermatopathol; 2021 Dec; 43(12):e146-e148. PubMed ID: 33795556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]